Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer

Gaurav Goyal, Anuhya Kommalapati, Adam C. Bartley, Tina M. Gunderson, Alex Adjei, Ronald S. Go

Research output: Contribution to journalArticle

Abstract

Background: Prior studies have shown superior surgical outcomes of stage I-III non-small cell lung cancer (NSCLC) in centers with higher patient volumes. However, there is a lack of such information in stage IV NSCLC. Patients and methods: This is a retrospective study of stage IV NSCLC patients diagnosed between 2004 and 2014 using the National Cancer Data Base (NCDB). We classified the total number of patients treated at facilities into quartiles: quartile 1 (Q1): ≤23; quartile 2 (Q2): 24–36, quartile 3 (Q3): 37–55, and quartile 4 (Q4): ≥56 cases/year. Cox regression was used to assess whether risk of death differed between quartiles after adjusting for demographics, insurance type, Charlson-Deyo score, and type of therapy received. Results: There were 338, 445 patients with stage IV NSCLC treated at 1326 facilities. We included the patients who received any form of therapy in the survival analysis. The unadjusted median overall survival by facility volume was: Q1: 6 months, Q2: 6 months, Q3: 7 months, and Q4: 8 months (p <.001). Multivariable analysis showed that facility volume was independent predictor of all-cause mortality. Compared with patients treated at Q4 facilities, patients treated at lower-quartile facilities had a small but significantly higher risk of death (Q3 hazard ratio [HR], 1.05 [95%CI, 1.04–1.06]; Q2 HR, 1.12 [95%CI, 1.11–1.14]; Q1 HR, 1.11 [95%CI, 1.10–1.12]). Conclusions: Patients who were treated for stage IV NSCLC at highest-volume facilities had less risk of all-cause mortality compared with those who were treated at lower-volume facilities. Although the survival advantage of being treated at highest-volume facilities appeared small, the results of this study suggest differences in cancer care delivery models among various facilities, and may become more relevant in the future era of personalized treatment of stage IV NSCLC.

Original languageEnglish (US)
Pages (from-to)214-219
Number of pages6
JournalLung Cancer
Volume122
DOIs
StatePublished - Aug 1 2018

Fingerprint

Hospital Mortality
Non-Small Cell Lung Carcinoma
Survival
Mortality
Survival Analysis
Insurance
Neoplasms
Therapeutics
Retrospective Studies
Demography
Databases

Keywords

  • Hospital volumes
  • Lung cancer
  • NCDB
  • Overall survival

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer. / Goyal, Gaurav; Kommalapati, Anuhya; Bartley, Adam C.; Gunderson, Tina M.; Adjei, Alex; Go, Ronald S.

In: Lung Cancer, Vol. 122, 01.08.2018, p. 214-219.

Research output: Contribution to journalArticle

Goyal, Gaurav ; Kommalapati, Anuhya ; Bartley, Adam C. ; Gunderson, Tina M. ; Adjei, Alex ; Go, Ronald S. / Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer. In: Lung Cancer. 2018 ; Vol. 122. pp. 214-219.
@article{0b0d86b0d81d4ebc8193f7789bc55a0e,
title = "Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer",
abstract = "Background: Prior studies have shown superior surgical outcomes of stage I-III non-small cell lung cancer (NSCLC) in centers with higher patient volumes. However, there is a lack of such information in stage IV NSCLC. Patients and methods: This is a retrospective study of stage IV NSCLC patients diagnosed between 2004 and 2014 using the National Cancer Data Base (NCDB). We classified the total number of patients treated at facilities into quartiles: quartile 1 (Q1): ≤23; quartile 2 (Q2): 24–36, quartile 3 (Q3): 37–55, and quartile 4 (Q4): ≥56 cases/year. Cox regression was used to assess whether risk of death differed between quartiles after adjusting for demographics, insurance type, Charlson-Deyo score, and type of therapy received. Results: There were 338, 445 patients with stage IV NSCLC treated at 1326 facilities. We included the patients who received any form of therapy in the survival analysis. The unadjusted median overall survival by facility volume was: Q1: 6 months, Q2: 6 months, Q3: 7 months, and Q4: 8 months (p <.001). Multivariable analysis showed that facility volume was independent predictor of all-cause mortality. Compared with patients treated at Q4 facilities, patients treated at lower-quartile facilities had a small but significantly higher risk of death (Q3 hazard ratio [HR], 1.05 [95{\%}CI, 1.04–1.06]; Q2 HR, 1.12 [95{\%}CI, 1.11–1.14]; Q1 HR, 1.11 [95{\%}CI, 1.10–1.12]). Conclusions: Patients who were treated for stage IV NSCLC at highest-volume facilities had less risk of all-cause mortality compared with those who were treated at lower-volume facilities. Although the survival advantage of being treated at highest-volume facilities appeared small, the results of this study suggest differences in cancer care delivery models among various facilities, and may become more relevant in the future era of personalized treatment of stage IV NSCLC.",
keywords = "Hospital volumes, Lung cancer, NCDB, Overall survival",
author = "Gaurav Goyal and Anuhya Kommalapati and Bartley, {Adam C.} and Gunderson, {Tina M.} and Alex Adjei and Go, {Ronald S.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.lungcan.2018.06.025",
language = "English (US)",
volume = "122",
pages = "214--219",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer

AU - Goyal, Gaurav

AU - Kommalapati, Anuhya

AU - Bartley, Adam C.

AU - Gunderson, Tina M.

AU - Adjei, Alex

AU - Go, Ronald S.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background: Prior studies have shown superior surgical outcomes of stage I-III non-small cell lung cancer (NSCLC) in centers with higher patient volumes. However, there is a lack of such information in stage IV NSCLC. Patients and methods: This is a retrospective study of stage IV NSCLC patients diagnosed between 2004 and 2014 using the National Cancer Data Base (NCDB). We classified the total number of patients treated at facilities into quartiles: quartile 1 (Q1): ≤23; quartile 2 (Q2): 24–36, quartile 3 (Q3): 37–55, and quartile 4 (Q4): ≥56 cases/year. Cox regression was used to assess whether risk of death differed between quartiles after adjusting for demographics, insurance type, Charlson-Deyo score, and type of therapy received. Results: There were 338, 445 patients with stage IV NSCLC treated at 1326 facilities. We included the patients who received any form of therapy in the survival analysis. The unadjusted median overall survival by facility volume was: Q1: 6 months, Q2: 6 months, Q3: 7 months, and Q4: 8 months (p <.001). Multivariable analysis showed that facility volume was independent predictor of all-cause mortality. Compared with patients treated at Q4 facilities, patients treated at lower-quartile facilities had a small but significantly higher risk of death (Q3 hazard ratio [HR], 1.05 [95%CI, 1.04–1.06]; Q2 HR, 1.12 [95%CI, 1.11–1.14]; Q1 HR, 1.11 [95%CI, 1.10–1.12]). Conclusions: Patients who were treated for stage IV NSCLC at highest-volume facilities had less risk of all-cause mortality compared with those who were treated at lower-volume facilities. Although the survival advantage of being treated at highest-volume facilities appeared small, the results of this study suggest differences in cancer care delivery models among various facilities, and may become more relevant in the future era of personalized treatment of stage IV NSCLC.

AB - Background: Prior studies have shown superior surgical outcomes of stage I-III non-small cell lung cancer (NSCLC) in centers with higher patient volumes. However, there is a lack of such information in stage IV NSCLC. Patients and methods: This is a retrospective study of stage IV NSCLC patients diagnosed between 2004 and 2014 using the National Cancer Data Base (NCDB). We classified the total number of patients treated at facilities into quartiles: quartile 1 (Q1): ≤23; quartile 2 (Q2): 24–36, quartile 3 (Q3): 37–55, and quartile 4 (Q4): ≥56 cases/year. Cox regression was used to assess whether risk of death differed between quartiles after adjusting for demographics, insurance type, Charlson-Deyo score, and type of therapy received. Results: There were 338, 445 patients with stage IV NSCLC treated at 1326 facilities. We included the patients who received any form of therapy in the survival analysis. The unadjusted median overall survival by facility volume was: Q1: 6 months, Q2: 6 months, Q3: 7 months, and Q4: 8 months (p <.001). Multivariable analysis showed that facility volume was independent predictor of all-cause mortality. Compared with patients treated at Q4 facilities, patients treated at lower-quartile facilities had a small but significantly higher risk of death (Q3 hazard ratio [HR], 1.05 [95%CI, 1.04–1.06]; Q2 HR, 1.12 [95%CI, 1.11–1.14]; Q1 HR, 1.11 [95%CI, 1.10–1.12]). Conclusions: Patients who were treated for stage IV NSCLC at highest-volume facilities had less risk of all-cause mortality compared with those who were treated at lower-volume facilities. Although the survival advantage of being treated at highest-volume facilities appeared small, the results of this study suggest differences in cancer care delivery models among various facilities, and may become more relevant in the future era of personalized treatment of stage IV NSCLC.

KW - Hospital volumes

KW - Lung cancer

KW - NCDB

KW - Overall survival

UR - http://www.scopus.com/inward/record.url?scp=85048867375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048867375&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2018.06.025

DO - 10.1016/j.lungcan.2018.06.025

M3 - Article

C2 - 30032834

AN - SCOPUS:85048867375

VL - 122

SP - 214

EP - 219

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -